Scott Lokey

Professor at UC Santa Cruz; founder's academic mentor

Appears in 1 story

Last updated Nov 10, 2026

Stories

argenx buys a peptide chemistry company to build oral immunology drugs

Money Moves

Not part of the transaction

Every medicine argenx sells today reaches patients by infusion or injection. On Nov. 9, 2026, the Dutch immunology company agreed to pay $550 million in cash for a Santa Cruz company whose chemistry is built to make pills instead.

Updated 1 hour ago